These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29749705)

  • 1. Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome.
    Gargari G; Taverniti V; Gardana C; Cremon C; Canducci F; Pagano I; Barbaro MR; Bellacosa L; Castellazzi AM; Valsecchi C; Tagliacarne SC; Bellini M; Bertani L; Gambaccini D; Marchi S; Cicala M; Germanà B; Dal Pont E; Vecchi M; Ogliari C; Fiore W; Stanghellini V; Barbara G; Guglielmetti S
    Environ Microbiol; 2018 Sep; 20(9):3201-3213. PubMed ID: 29749705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
    Mazzawi T; Hausken T; Hov JR; Valeur J; Sangnes DA; El-Salhy M; Gilja OH; Hatlebakk JG; Lied GA
    Scand J Gastroenterol; 2019 Jun; 54(6):690-699. PubMed ID: 31190584
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome.
    Tap J; Derrien M; Törnblom H; Brazeilles R; Cools-Portier S; Doré J; Störsrud S; Le Nevé B; Öhman L; Simrén M
    Gastroenterology; 2017 Jan; 152(1):111-123.e8. PubMed ID: 27725146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fecal short-chain fatty acids in non-constipated irritable bowel syndrome: a potential clinically relevant stratification factor based on catabotyping analysis.
    Gargari G; Mantegazza G; Taverniti V; Gardana C; Valenza A; Rossignoli F; Barbaro MR; Marasco G; Cremon C; Barbara G; Guglielmetti S
    Gut Microbes; 2023 Dec; 15(2):2274128. PubMed ID: 37910479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome.
    Ringel-Kulka T; Choi CH; Temas D; Kim A; Maier DM; Scott K; Galanko JA; Ringel Y
    Am J Gastroenterol; 2015 Sep; 110(9):1339-46. PubMed ID: 26303129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of Habitual Dietary Intake With Fecal Short-Chain Fatty Acids and Bowel Functions in Irritable Bowel Syndrome.
    Calderon G; Patel C; Camilleri M; James-Stevenson T; Bohm M; Siwiec R; Rogers N; Wo J; Lockett C; Gupta A; Xu H; Shin A
    J Clin Gastroenterol; 2022 Mar; 56(3):234-242. PubMed ID: 33780215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis.
    Sun Q; Jia Q; Song L; Duan L
    Medicine (Baltimore); 2019 Feb; 98(7):e14513. PubMed ID: 30762787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification.
    Lyra A; Rinttilä T; Nikkilä J; Krogius-Kurikka L; Kajander K; Malinen E; Mättö J; Mäkelä L; Palva A
    World J Gastroenterol; 2009 Dec; 15(47):5936-45. PubMed ID: 20014457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption.
    Jeffery IB; Das A; O'Herlihy E; Coughlan S; Cisek K; Moore M; Bradley F; Carty T; Pradhan M; Dwibedi C; Shanahan F; O'Toole PW
    Gastroenterology; 2020 Mar; 158(4):1016-1028.e8. PubMed ID: 31843589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of
    Chen L; Xu WL; Pei LX; Wu XL; Geng H; Guo J; Sun JH
    Zhongguo Zhen Jiu; 2021 Feb; 41(2):137-41. PubMed ID: 33788460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation.
    Tanaka Y; Yamashita R; Kawashima J; Mori H; Kurokawa K; Fukuda S; Gotoh Y; Nakamura K; Hayashi T; Kasahara Y; Sato Y; Fukudo S
    J Gastroenterol; 2022 Oct; 57(10):748-760. PubMed ID: 35908139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Maharshak N; Ringel Y; Katibian D; Lundqvist A; Sartor RB; Carroll IM; Ringel-Kulka T
    Dig Dis Sci; 2018 Jul; 63(7):1890-1899. PubMed ID: 29777439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ileocolonic Histopathological and Microbial Alterations in the Irritable Bowel Syndrome: A Nested Community Case-Control Study.
    Talley NJ; Alexander JL; Walker MM; Jones MP; Hugerth LW; Engstrand L; Agréus L; Powell N; Andreasson A
    Clin Transl Gastroenterol; 2020 Dec; 12(1):e00296. PubMed ID: 33464728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short chain fatty acids and monocarboxylate transporters in irritable bowel syndrome.
    Fredericks E; Theunissen R; Roux S
    Turk J Gastroenterol; 2020 Dec; 31(12):840-847. PubMed ID: 33625995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbial signatures of patients with diarrhea-predominant irritable bowel syndrome and their healthy relatives.
    Chen J; Lan H; Li C; Xie Y; Cheng X; Xia R; Ke C; Liang X
    J Appl Microbiol; 2024 Jun; 135(6):. PubMed ID: 38849305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal Fermentation in Irritable Bowel Syndrome: Influence of Dietary Restriction of Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols.
    Valeur J; Røseth AG; Knudsen T; Malmstrøm GH; Fiennes JT; Midtvedt T; Berstad A
    Digestion; 2016; 94(1):50-6. PubMed ID: 27487397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Ileal Immunoglobulin A Production and Immunoglobulin A-Coated Bacteria in Diarrhea-Predominant Irritable Bowel Syndrome.
    Liu Y; Yuan X; Li L; Lin L; Zuo X; Cong Y; Li Y
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00146. PubMed ID: 32352710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.
    Hong G; Li Y; Yang M; Li G; Qian W; Xiong H; Bai T; Song J; Zhang L; Hou X
    Neurogastroenterol Motil; 2020 Nov; 32(11):e13891. PubMed ID: 32449259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome.
    Duboc H; Rainteau D; Rajca S; Humbert L; Farabos D; Maubert M; Grondin V; Jouet P; Bouhassira D; Seksik P; Sokol H; Coffin B; Sabaté JM
    Neurogastroenterol Motil; 2012 Jun; 24(6):513-20, e246-7. PubMed ID: 22356587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome.
    El-Salhy M; Valeur J; Hausken T; Gunnar Hatlebakk J
    Neurogastroenterol Motil; 2021 Feb; 33(2):e13983. PubMed ID: 32945066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.